Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Date:6/4/2009

nce they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

        -- our ability to borrow additional amounts under the loan from Bay
           City Capital, which is subject to the discretion of Bay City
           Capital;
        -- our ability to obtain necessary financing in the near term,
           including amounts necessary to repay the loan from Bay City Capital
           by the September 14, 2009 maturity date (or earlier if certain
           repayment acceleration provisions are triggered);
        -- our ability to control our operating expenses;
        -- our ability to comply with covenants included in the loan from Bay
           City Capital;
        -- our ability to maintain the listing of our common stock on NASDAQ;
        -- our failure to timely recruit and enroll patients for the FDG-PET
           clinical trial, as well as any future clinical trial;
        -- our failure to obtain sufficient data from enrolled patients that
           can be used to evaluate VIA-2291, thereby impairing the validity or
           statistical significance of our clinical trials;
        -- our ability to successfully complete our clinical trials of
           VIA-2291 on expected timetables and the outcomes of such clinical
           trials;
        -- complexities in designing and implementing cardiovascular clinical
           trials using histological examinations, measurement of biomarkers,
           medical imaging and atherosclerotic plaque bioassays;
        -- the results of our clinical trials, including without limitation,
           with respect to the safety and efficacy of VIA-2291;
        -- if the results of
'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ...
(Date:12/24/2014)... SoundConnect’s 2015 next generation ... communication technology, provide continued education and inform users ... demonstrates online communication features and benefits; empowering users ... innovative and powerful tools. , According to SoundConnect’s ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... April 22 /Xinhua-PRNewswire/ -- Fufeng Group Limited,("Fufeng" or ... "the Group"; HKEx: 546), a leading vertically integrated,manufacturer ... results for the year ended 31 December 2007., ... sales volume of major,products, the Group,s turnover increased ...
... NATICK, Mass., April 21 Boston Scientific,Corporation (NYSE: BSX ... 31, 2008, as well as guidance for net sales and,earnings ... First quarter highlights:, -- Achieved net sales of ... earnings through ongoing, stringent expense management -- Maintained leading ...
... in Response to ... Consumer Demand for Water Safety, MONROVIA, Calif., ... this week, addressing consumer concerns,regarding private well water. Available now ... contaminants with easy-to-use,at-home results, most of which can be completed ...
Cached Biology Technology:Fufeng Announces 2007 Annual Results 2Fufeng Announces 2007 Annual Results 3Boston Scientific Announces Results for First Quarter Ended March 31, 2008 2Boston Scientific Announces Results for First Quarter Ended March 31, 2008 3Boston Scientific Announces Results for First Quarter Ended March 31, 2008 4Boston Scientific Announces Results for First Quarter Ended March 31, 2008 5Boston Scientific Announces Results for First Quarter Ended March 31, 2008 6Boston Scientific Announces Results for First Quarter Ended March 31, 2008 7Boston Scientific Announces Results for First Quarter Ended March 31, 2008 8Boston Scientific Announces Results for First Quarter Ended March 31, 2008 9Boston Scientific Announces Results for First Quarter Ended March 31, 2008 10Boston Scientific Announces Results for First Quarter Ended March 31, 2008 11Boston Scientific Announces Results for First Quarter Ended March 31, 2008 12Boston Scientific Announces Results for First Quarter Ended March 31, 2008 13Boston Scientific Announces Results for First Quarter Ended March 31, 2008 14Boston Scientific Announces Results for First Quarter Ended March 31, 2008 15Boston Scientific Announces Results for First Quarter Ended March 31, 2008 16Boston Scientific Announces Results for First Quarter Ended March 31, 2008 17Boston Scientific Announces Results for First Quarter Ended March 31, 2008 18Silver Lake Research Unveils Watersafe(R) Well Water Test Kit 2
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... Center for Vaccine Awareness and Research at Texas Childrens ... major cocoon strategy vaccination program to protect newborn infants ... whooping cough. , Whooping cough is a highly-contagious bacterial ... occur at any age, whooping cough can be particularly ...
... 25, 2008) The American Society for Neural Therapy and ... at the Sheraton Sand Key Resort in Clearwater, Florida. ... may be submitted electronically at www.asntr.org and travel ... site. Celebrating its 15th anniversary in 2008, the ASNTR is ...
... hold the answer to making solar cells a more ... Engineering Physics at McMaster University, Cleanfield Energy and the ... to pursue the commercialization of nanowire technology in the ... nanowire technology developed at McMaster is able to trap ...
Cached Biology News:Texas Hospital nation's first to use large-scale 'cocoon strategy' against whooping cough 2ASNTR 15th anniversary meeting to be held May 1-3 in Florida 2Nanowires hold promise for more affordable solar cells 2
Imject Freund's Incomplete Adjuvant (FIA)...
... XL extends the MSn performance of the ... tools to generate extensive structural information for ... , Multiple dissociation techniques (PQD, ETD, ... unpredicted metabolites , Fast polarity switching for ...
... effective - Utilizes hands-off homogenization through a vortex ... grinding - Extract DNA without hand grinding; eliminating ... , Robust tubes - Includes tough ... tube breakage , Flexible format - ...
... The LXQ linear ion trap mass ... paced analytical laboratory., The LXQ linear ion ... discovery and proteomic applications, delivering the fast ... Thermo linear ion trap at an attractive ...
Biology Products: